Title: Development and evaluation of a predictive model of upper gastrointestinal bleeding in
liver cirrhosis
Version: 2 Date: 22 Dec 2024
Reviewer:  Billy Siahaan
Reviewer's report:
Comment from reviewer :
1.Congratulation for your work , but I still confused about the method of collecting data and
method you use in this study. Could you describe more detail about “who experienced UGIB
within six months of discharge, were included in the study” , is the laboratory , fibroscan and
endoscopy were conducted  at the same time of hospitalisation ?  or all the variable were
collecting before any important treatment that may altered the result ?
2.I recommend you get additional exclusion regarding portal vein thrombosis or any non
cirrhotic condition that may have a different value from the spleen stiffness measurement and
the prognostic
3.“Of these, 99 patients had hepatitis B “ , what about the other etiology ? could you describe
and include in your baseline characteristic ? Its also important to difference between the use of
antiviral treatment because it has difference result in my opinion
4.If you had etiologies from MAFLD , I am not sure if the cholesterol level maybe altered and
could be a big bias for this research.
5. Could you describe what fibroscan type do you used especially for measurement of spleen
stiffness? Because the accuracy is different between 50 hz and 100hz ( spleen dedicated
fibroscan)
6.In this research you compare the model with other models like child pugh score. Could you
describe more detail about the method you used for get AUC from child pugh score model in
correlation with the upper gastrointestinal bleeding event
7.Did you had any record regarding the use of albumin transfusion during treatment at the
hospital? Please describe more detail especially in the variable that related to the study
Title: Development and evaluation of a predictive model of upper gastrointestinal bleeding in
liver cirrhosis
Version: 2 Date: 22 Dec 2024
Reviewer:  Billy Siahaan
Reviewer's report:
Comment from reviewer :
1.Congratulation for your work , but I still confused about the method of collecting data and
method you use in this study. Could you describe more detail about “who experienced UGIB
within six months of discharge, were included in the study” , is the laboratory , fibroscan and
endoscopy were conducted  at the same time of hospitalisation ?  or all the variable were
collecting before any important treatment that may altered the result ?
2.I recommend you get additional exclusion regarding portal vein thrombosis or any non
cirrhotic condition that may have a different value from the spleen stiffness measurement and
the prognostic
3.“Of these, 99 patients had hepatitis B “ , what about the other etiology ? could you describe
and include in your baseline characteristic ? Its also important to difference between the use of
antiviral treatment because it has difference result in my opinion
4.If you had etiologies from MAFLD , I am not sure if the cholesterol level maybe altered and
could be a big bias for this research.
5. Could you describe what fibroscan type do you used especially for measurement of spleen
stiffness? Because the accuracy is different between 50 hz and 100hz ( spleen dedicated
fibroscan)
6.In this research you compare the model with other models like child pugh score. Could you
describe more detail about the method you used for get AUC from child pugh score model in
correlation with the upper gastrointestinal bleeding event
7.Did you had any record regarding the use of albumin transfusion during treatment at the
hospital? Please describe more detail especially in the variable that related to the study
Please review this paper.
user
Title: Development and evaluation of a predictive model of upper gastrointestinal bleeding in
liver cirrhosis
Version: 2 Date: 22 Dec 2024
Reviewer:  Billy Siahaan
Reviewer's report:
Comment from reviewer :
1.Congratulation for your work , but I still confused about the method of collecting data and
method you use in this study. Could you describe more detail about “who experienced UGIB
within six months of discharge, were included in the study” , is the laboratory , fibroscan and
endoscopy were conducted  at the same time of hospitalisation ?  or all the variable were
collecting before any important treatment that may altered the result ?
2.I recommend you get additional exclusion regarding portal vein thrombosis or any non
cirrhotic condition that may have a different value from the spleen stiffness measurement and
the prognostic
3.“Of these, 99 patients had hepatitis B “ , what about the other etiology ? could you describe
and include in your baseline characteristic ? Its also important to difference between the use of
antiviral treatment because it has difference result in my opinion
4.If you had etiologies from MAFLD , I am not sure if the cholesterol level maybe altered and
could be a big bias for this research.
5. Could you describe what fibroscan type do you used especially for measurement of spleen
stiffness? Because the accuracy is different between 50 hz and 100hz ( spleen dedicated
fibroscan)
6.In this research you compare the model with other models like child pugh score. Could you
describe more detail about the method you used for get AUC from child pugh score model in
correlation with the upper gastrointestinal bleeding event
7.Did you had any record regarding the use of albumin transfusion during treatment at the
hospital? Please describe more detail especially in the variable that related to the study
assistant